On the commercialization front, Teva will lead in Europe, Israel and specified countries while Sanofi will take the helm in North America, Japan, certain parts of Asia and the rest of the world.
Astellas inks $1.9B strategic collab with Cullgen to progress protein degraders
From a financial perspective, Sonoma will receive a $30 million equity investment from Regeneron, $45 million in cash and is eligible to receive a $45 million development milestone payment.
Life sciences collective NPG Health is launching in tandem with marketing agency Bliss Bio Health, both of which will focus on R&D research, medical education and advertising.
Gilead partners with EVOQ Therapeutics, bolstering its rheumatoid arthritis and lupus pipeline